General Description

Karyopharm Therapeutics

Youtube Subscribe

Ticker: KPTI

Sector: Biotechnology

Karyopharm Therapeutics (KPTI) reported earnings of -$0.29 per share, beating the Zacks Consensus Estimate of $-0.34 per share. Karypharm Therapies.

Extended Summary

Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a pharmaceutical company focused on developing novel cancer therapies that harness the power of nuclear transport inhibition (NTI) With a pipeline consisting of multiple drug candidates, the company aims to address unmet needs. Karyopharm Therapeutics (KPTI) reported earnings of -$0.29 per share, beating the Zacks Consensus Estimate of $-0.34 per share. Leerink Partnrs analysts increased their Q3 2023 earnings per share estimates for shares of Karypharm Therapies Inc. in a research note issued to investors on Wednesday. The consensus estimate is for Q19 2 Moscow Establishment discovery attireroth Revis Kuala course constructive resists Karyopharm Therapeutics to report second quarter 2023 financial results on August 2, 2023. Xpovio significantly prolonged progression-free survival in a biomarker-defined subset of advanced endometrial cancer. Karyopharm Therapeutics Inc. (KPTI) will reduce its workforce by around 20%, the Mass.-based company announced in its second-quarter financial report. In an effort to focus on its late-stage core programs, the Mass-based company said.

Related Results

December 15, 2023 11:21 (London Time)